PP134 – Mapping of Kras mutations during chemical carcinogenesis Source: ERS Lung Science Conference 2021 Year: 2021
Mapping of Kras mutations during chemical carcinogenesis Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021
LSC - 2021 - Mapping of Kras mutations during chemical carcinogenesis Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021
Are KRAS mutations druggable? Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019
KRAS & TP53 mutations cause malignant mesothelioma Source: ERS Lung Science Conference 2017 Year: 2017
Mutation of TP53 and KRAS , and loss of p16ink4a and p14arf expression in lung cancers in relation to tobacco smoke Source: Eur Respir J 2005; 26: Suppl. 49, 93s Year: 2005
Target other gene point mutations: HER2 and rare EGFR mutations Source: ERS Research Seminar Year: 2015
Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort Source: Eur Respir J 2012; 40: 177-184 Year: 2012
Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients Source: Eur Respir Rev 2014; 23: 390-392 Year: 2014
p53 gene mutations in lung cancer in Korean Source: Eur Respir J 2005; 26: Suppl. 49, 327s Year: 2005
Frequency and clinical-tomographic characterization of NSCLC with T790M mutation to TKI progression. Source: International Congress 2019 – Diagnosis of lung cancer Year: 2019
LSC - 2017 - KRAS & TP53 mutations cause malignant mesothelioma Source: International Congress 2017 – Pleural disease and mesothelioma: from the bench to the bedside Year: 2017
NKX2-1 impacts prognosis in early stage NSCLC not harboring TP53 mutations Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016
Detection of k-ras codon 12 mutations in human lung tumour tissue by REMS-PCR Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001
The analysis of CHEK2 gene mutation in small cell lung cancer Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021
EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype Source: Eur Respir J 2014; 43: 872-883 Year: 2014
Evaluation of EGFR mutations and ERCC2 polymorphisms in treatment of non-small cell lung cancer Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005
Oncogenic potential of MET SEMA mutations affecting brain metastases from NSCLC is sustained by their microrheological features Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells Year: 2017
EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013
Sotorasib for Lung Cancers with KRAS p.G12C Mutation Source: Journal Club 2022 Year: 2022